American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

ASCO SIGN IN

Manage Email Subscriptions

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

ASCO Membership Directory

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Practice & Guidelines

Guidelines

Clinical Practice Guidelines

American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

Published in the Journal of Clinical Oncology. vol 29. No 29 (October 10): 3939-3942

Jennifer J. Griggs, Mark R. Somerfield, Holly Anderson, Nora Lynn Henry, Clifford Hudis, James L. Khatcheressian, Ann H. Partridge, Ann Alexis Prestrud, Nancy E. Davidson

Purpose: The American Society of Clinical Oncology (ASCO) has policies and procedures for endorsing practice guidelines that have been developed by other professional organizations.

Methods: The Cancer Care Ontario (CCO) Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer was reviewed for developmental rigor by methodologists. An ad hoc review panel of experts reviewed the content.

Results: The ASCO ad hoc OA guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. According to the CCO guideline: one, OA should not be routinely added to systemic therapy with chemotherapy, tamoxifen, or the combination of tamoxifen and chemotherapy; two, OA alone is not recommended as an alternative to any other form of systemic therapy, except in the specific case of patients who are candidates for other forms of systemic therapy but who for some reason will not receive any other systemic therapy (eg, patients who cannot tolerate other forms of systemic therapy or patients who choose no other form of systemic therapy); and three, when chemical suppression using luteinizing hormone– releasing hormone agonists is the chosen method of OA, in the opinion of the Breast Cancer Disease Site Group, monthly injection is the recommended mode of administration. The mode of administration in nearly all of the available trials has been monthly administration.

Conclusion: The ASCO review panel agrees with the recommendations as stated in the CCO guideline, with the qualification that ongoing research studies may alter the recommendations of the panel.

To discuss this guideline, visit the ASCOconnection.org Practice forum. Log in with your asco.org username and password to comment.

The guideline endorsement is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines and endorsements do not account for individual variation among patients and may not reflect the most recent evidence. The guideline endorsement does not recommend any particular product or course of medical treatment. Use of the guideline endorsement is voluntary.

Last Updated: 9/16/11